Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform

Area of Science:

• Pharmaceutical industry
• Intellectual property law
• Healthcare policy

Background:

• Brand-name pharmaceutical manufacturers utilize strategies like patent thickets and product hops to extend market exclusivity and limit generic competition.
• These tactics are particularly prevalent for drug-device combinations, such as inhalers and specific diabetes medications, complicating generic market entry.
• Existing legislative efforts aim to expedite generic competition, but further reforms are necessary to address pervasive patent "gamesmanship".

Purpose of the Study:

• To analyze the impact of patent thickets and product hops on generic drug competition.
• To evaluate the effectiveness of current legislative proposals in facilitating timely generic entry.
• To propose additional reforms to curb anticompetitive patent practices in the pharmaceutical sector.

Main Methods:

• Analysis of patenting strategies employed by brand-name pharmaceutical companies.
• Review of legislative actions and proposals concerning pharmaceutical patent reform.
• Examination of challenges in generic drug approval, particularly for complex drug-device combinations.

Main Results:

• Patent thickets (numerous patents on peripheral features) and product hops (reformulations with new patents) effectively delay generic competition.
• Drug-device combinations are especially susceptible to these delaying tactics, extending market exclusivity.
• Current legislative efforts represent a step forward but are insufficient to fully address the issue.

Conclusions:

• Further reforms are essential to limit pharmaceutical patent gamesmanship and promote timely generic competition.
• Recommendations include USPTO reexamination of patents, enhanced FDA oversight, limits on infringement lawsuits, stronger incentives for patent challenges, and increased FDA flexibility for complex generics.
• Implementing these reforms can lead to more accessible and affordable medications for patients.